Amneal Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 6, 2020 6:10 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $519 million versus the consensus estimate of $482.11 million.
Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company... More
